158 related articles for article (PubMed ID: 34073849)
1. Isolation and Establishment of a Highly Proliferative, Cancer Stem Cell-Like, and Naturally Immortalized Triple-Negative Breast Cancer Cell Line, KAIMRC2.
Ali R; Al Zahrani H; Barhoumi T; Alhallaj A; Mashhour A; Alshammari MA; Alshawakir YA; Baz O; Alanazi AH; Khan AL; Al Nikhli H; Al Balwi MA; Al Riyees L; Boudjelal M
Cells; 2021 May; 10(6):. PubMed ID: 34073849
[TBL] [Abstract][Full Text] [Related]
2. Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133
Brugnoli F; Grassilli S; Lanuti P; Marchisio M; Al-Qassab Y; Vezzali F; Capitani S; Bertagnolo V
BMC Cancer; 2017 Sep; 17(1):617. PubMed ID: 28870198
[TBL] [Abstract][Full Text] [Related]
3. The Milk Protein Alpha-Casein Suppresses Triple Negative Breast Cancer Stem Cell Activity Via STAT and HIF-1alpha Signalling Pathways in Breast Cancer Cells and Fibroblasts.
Garner KEL; Hull NJ; Sims AH; Lamb R; Clarke RB
J Mammary Gland Biol Neoplasia; 2019 Sep; 24(3):245-256. PubMed ID: 31529195
[TBL] [Abstract][Full Text] [Related]
4. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
5. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
6. Elucidation of Altered Pathways in Tumor-Initiating Cells of Triple-Negative Breast Cancer: A Useful Cell Model System for Drug Screening.
Christensen AG; Ehmsen S; Terp MG; Batra R; Alcaraz N; Baumbach J; Noer JB; Moreira J; Leth-Larsen R; Larsen MR; Ditzel HJ
Stem Cells; 2017 Aug; 35(8):1898-1912. PubMed ID: 28600813
[TBL] [Abstract][Full Text] [Related]
7. Signaling pathways essential for triple-negative breast cancer stem-like cells.
Ehmsen S; Ditzel HJ
Stem Cells; 2021 Feb; 39(2):133-143. PubMed ID: 33211379
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional profiles of different states of cancer stem cells in triple-negative breast cancer.
Liu M; Liu Y; Deng L; Wang D; He X; Zhou L; Wicha MS; Bai F; Liu S
Mol Cancer; 2018 Feb; 17(1):65. PubMed ID: 29471829
[TBL] [Abstract][Full Text] [Related]
10. CD49f-positive cell population efficiently enriches colon cancer-initiating cells.
Haraguchi N; Ishii H; Mimori K; Ohta K; Uemura M; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Doki Y; Mori M
Int J Oncol; 2013 Aug; 43(2):425-30. PubMed ID: 23708747
[TBL] [Abstract][Full Text] [Related]
11. A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer.
Kaur S; Elkahloun AG; Singh SP; Chen QR; Meerzaman DM; Song T; Manu N; Wu W; Mannan P; Garfield SH; Roberts DD
Oncotarget; 2016 Mar; 7(9):10133-52. PubMed ID: 26840086
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic, structural, and ultrastructural analysis of triple-negative breast cancer cell lines and breast cancer stem cell subpopulation.
Moreira MP; Brayner FA; Alves LC; Cassali GD; Silva LM
Eur Biophys J; 2019 Oct; 48(7):673-684. PubMed ID: 31485678
[TBL] [Abstract][Full Text] [Related]
13. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
[TBL] [Abstract][Full Text] [Related]
14. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency.
Atkinson RL; Yang WT; Rosen DG; Landis MD; Wong H; Lewis MT; Creighton CJ; Sexton KR; Hilsenbeck SG; Sahin AA; Brewster AM; Woodward WA; Chang JC
Breast Cancer Res; 2013; 15(5):R77. PubMed ID: 24008095
[TBL] [Abstract][Full Text] [Related]
15. Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.
Doherty MR; Cheon H; Junk DJ; Vinayak S; Varadan V; Telli ML; Ford JM; Stark GR; Jackson MW
Proc Natl Acad Sci U S A; 2017 Dec; 114(52):13792-13797. PubMed ID: 29229854
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
[TBL] [Abstract][Full Text] [Related]
17. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
[TBL] [Abstract][Full Text] [Related]
18. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
[TBL] [Abstract][Full Text] [Related]
19. STAT3 as a promising chemoresistance biomarker associated with the CD44
Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states.
Sulaiman A; McGarry S; Li L; Jia D; Ooi S; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Gadde S; Li X; Wang L
Mol Oncol; 2018 Apr; 12(4):423-440. PubMed ID: 29316250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]